BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 20700114)

  • 1. Sex differences in performance of fecal occult blood testing.
    Brenner H; Haug U; Hundt S
    Am J Gastroenterol; 2010 Nov; 105(11):2457-64. PubMed ID: 20700114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
    Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
    Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of guaiac-based fecal occult blood test in routine screening: state-wide analysis from Bavaria, Germany.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Am J Gastroenterol; 2014 Mar; 109(3):427-35. PubMed ID: 24343548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance improvements of stool-based screening tests.
    van Dam L; Kuipers EJ; van Leerdam ME
    Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):479-92. PubMed ID: 20833351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.
    Oort FA; Terhaar Sive Droste JS; Van Der Hulst RW; Van Heukelem HA; Loffeld RJ; Wesdorp IC; Van Wanrooij RL; De Baaij L; Mutsaers ER; van der Reijt S; Coupe VM; Berkhof J; Bouman AA; Meijer GA; Mulder CJ
    Aliment Pharmacol Ther; 2010 Feb; 31(3):432-9. PubMed ID: 19878150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal occult blood testing.
    Sanford KW; McPherson RA
    Clin Lab Med; 2009 Sep; 29(3):523-41. PubMed ID: 19840685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of serum markers for the early detection of colorectal cancer.
    Wild N; Andres H; Rollinger W; Krause F; Dilba P; Tacke M; Karl J
    Clin Cancer Res; 2010 Dec; 16(24):6111-21. PubMed ID: 20798228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The positive predictive value of guaiac faecal occult blood test in relation to the number of positive squares in two consecutive rounds of colorectal cancer screening.
    Manfredi S; Philip J; Campillo B; Piette C; Durand G; Riou F; Bretagne JF
    Eur J Cancer Prev; 2011 Jul; 20(4):277-82. PubMed ID: 21633201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New fecal occult blood tests may improve adherence and mortality rates.
    Kumaravel V; Hayden SP; Hall GS; Burke CA
    Cleve Clin J Med; 2011 Aug; 78(8):515-20. PubMed ID: 21807923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
    Brenner H; Tao S
    Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New stool screening tests for colorectal cancer.
    Young GP; Cole S
    Digestion; 2007; 76(1):26-33. PubMed ID: 17947816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stool occult blood testing: comparison.
    Wiwanitkit V
    Am J Gastroenterol; 2010 Dec; 105(12):2709. PubMed ID: 21131944
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
    Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
    Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well adjusted qualitative immunochemical faecal occult blood tests could be a promising alternative for inexpensive, high-quality colorectal cancer screening.
    Tao S; Brenner H
    Eur J Cancer Prev; 2013 Jul; 22(4):305-10. PubMed ID: 23702679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.